Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab with topical corticosteroids in pediatric moderate-to-severe atopic dermatitis
2021-000448-23Phase 2Active
- Sponsor
- Galderma
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nemolizumab in atopic dermatitis (AD) (2 arms), sponsored by Galderma. Primary endpoints: Pharmacokinetics of nemolizumab and Safety of nemolizumab. Started Aug 2021; status: active.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2021-000448-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000448-23.